Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia

International Journal of Clinical Practice

Volumn 52, Issue 6, 1998, Pages 402-407

  Kirby, R S ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN;

ANTIHYPERTENSIVE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; BLOOD PRESSURE; DOXAZOSIN; HUMANS; MALE; PATIENT SELECTION; PROSTATIC HYPERPLASIA; URODYNAMICS;

EID: 0031683623     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-471.
2. Barry MJ, Cockett ATK, Holtgrewe HL et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150: 351-358.
3. Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979; 122: 487-491.
4. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193-201.
5. Furuya S, Kumamoto Y, Yokoyama E et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128: 836-839.
6. Chapple CR, Aubry ML, James S et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol 1989; 63: 487-496.
7. James S, Chapple CR, Phillips MI et al. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol 1989; 142: 438-444.
8. Chapple CR, Noble JG, Milroy EJG. Comparative study of selective α1-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. Br J Urol 1993; 72: 822-825.
9. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC, and Writing Committee. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243-247.
10. Wasson JH, Reda DJ, Bruskewitz RC et al, for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-79.
11. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guidelines, No 8. Rockville, Md: US Department of Health and Human Services, Feb 1994.
12. Ruffolo Jr RR, Nichols AJ, Stadel JM, Hieble JP. Structure and function of α-adrenoceptors. Pharmacol Rev 1991; 43: 475-505.
13. Bylund DB, Eikenberg DC, Hieble JP et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994; 46: 121-136.
14. Ford APDW, Williams TJ, Blue DR, Clarke DE. α1-adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol Sci 1994; 15: 167-170.
15. Yamada S, Tanaka C, Kimura R, Kawabe K. Alpha 1-adrenoceptors in human prostate: characterization and binding characteristics of alpha 1 antagonists. Life Sci 1994; 54: 1845-1854.
16. Wilde MI, Fitton A, McTavish D. Alfuzosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993; 45: 410-428.
17. Kenny BA, Read AM, Naylor AM et al. Effect of alpha-1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urology 1994; 44: 52-56.
18. Forray C, Bard JA, Wetzel JM et al. The α1-adrenergic receptor that mediates smooth muscle contraction in the human prostate has the pharmacological properties of the cloned human α1c subtype. Mol Pharmacol 1994; 45: 703-709.
19. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551-554.
20. Abrams PH, Shah PJR, Stone R, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982; 54: 527-530.
21. Caine M, Perlberg S, Shapiro A. Phenoxybenzamine for benign prostatic obstruction: review of 200 cases. Urology 1981; XVII: 542-546.
22. Kirby RS, Coppinger SWC, Corcoran MO et al. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Urol 1987; 60: 136-142.
23. Hedlund H, Andersson KE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983; 130: 275-278.
24. Janknegt RA, Chapple CR. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia: analysis of 5 studies. Eur Urol 1993; 24: 319-326.
25. Fulton B, Wagstaff AJ, Sorkin EG. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320.
26. Fawzy A, Braun K, Lewis GP et al, for the Multicenter Study Group. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-109.
27. Gillenwater JY, Conn RL, Chrysant SG et al, for Multicenter Study Group. Doxazosin for the treatment of benign prostatic hyperplasia inpatients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-115.
28. Lepor H. Long-term efficacy and safety of doxazosin for the treatment of benign prostatic hyperplasia. J Urol 1995; 153: 273A.
29. Holme JB, Christensen MM, Rasmussen PC et al. 29-weeks-doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand J Urol 1994; 28: 77-80.
30. Kirby RS. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. Br J Clin Pract 1994; (suppl 74): 23-29.
31. Kirby RS. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995; 46: 182-186.
32. Kaplan SA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia: a study of safety and efficacy. Urology 1995; 46: 512-517.
33. Pool JL. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 1991; 121: 251-260.
34. Neaton JD, Grimm RH, Prineas RJ et al. Treatment of Mild Hypertension Study: final results. JAMA 1993; 270(6): 713-724.
35. Pool JL. Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. Br J Clin Pract 1994; 74: 8-12.
36. Holme I, Fauchald P, Rugstad HE, Stokke HP. Preliminary results of the Norwegian doxazosin postmarketing surveillance study: a twelve-week experience. Am Heart J 1991; 121: 260-267.
37. Langdon CG. Doxazosin in hypertension: results of a general practice study in 4809 patients. Br J Clin Pract 1994; 48: 293-298.
38. Itskovitz HD. Alpha I blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther 1994; 16: 490-504.
39. Grimm RH, for the TOMHS Research Group. Results of 24 months' treatment of mild hypertension: the TOMHS study. Scientific exhibit, 1991.
40. Chapple CR. Role of alpha adrenergic blocking drugs in the treatment of bladder outflow obstruction. European Urology Update, Series 2: No 21. London: European Board of Urology, 1993.
41. Lepor H, Tang R, Shapiro E. The alpha adrenoceptor subtype mediating the tension of human smooth muscle. Prostate 1993; 22: 301-307.
42. Shapiro E, Hartano V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297-307.
43. Kaplan SA, Goluboff ET, Olsson CA et al. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 1995; 45: 398-405.
44. Kirby RS, Pool JL. Alpha blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol 1997; 80: 521-532.